Výsledky vyhledávání - "Jason Shpilsky"

Training Hematologists/Oncologists for the Academic-Community Hybrid: Creating a Fellowship Framework for the Future

Autor: Daniel A. Roberts, Jennifer Faig, Kelly Bodio-Downey, Jason Shpilsky, Kathleen Leahy, Jonathan Wischhusen, Sara Giordano, Utkarsh Acharya, Reed Drews, David Dougherty, Christopher Lathan, Deepa Rangachari

Publikováno v: JCO oncology practice.

PURPOSE: Conventional hematology/oncology fellowship training is designed to foster careers in academic practice through intensive exposure to clinical and laboratory research. Even so, a notable proportion of graduating fellows opt to pursue a clini

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f87ea786e4577d3f25b5efe4da7a7d6b
https://pubmed.ncbi.nlm.nih.gov/36534931

Zobrazit plný text záznamu

First-Line Immunotherapy Combinations in Advanced Renal Cell Carcinoma: A Rapid Review and Meta-Analysis

Autor: David F. McDermott, Jason Shpilsky, Paul J. Catalano

Publikováno v: Kidney Cancer. 5:153-163

BACKGROUND: Combination or multi-agent therapy including immune checkpoint inhibitors has shifted the landscape of the treatment of advanced/metastatic renal cell carcinoma. There are several approved immune checkpoint inhibitor (ICI) combinations fe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6b50e40347cf384ddc2578a232d1e099
https://doi.org/10.3233/kca-210120

Zobrazit plný text záznamu

EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but Eventually Acquire EGFR T790M/C797S in Preclinical Models and Clinical Samples

Autor: Jason Shpilsky, Pasi A. Jänne, Christie J. Lau, Geoffrey R. Oxnard, Ciric To, Daniel B. Costa, Paul A. VanderLaan, Cloud P. Paweletz, Deepa Rangachari, Mierzhati Mushajiang, Susumu Kobayashi

Publikováno v: Journal of Thoracic Oncology. 14:1995-2002

Introduction Osimertinib is approved for advanced EGFR-mutated NSCLC, and identification of on-target mechanisms of resistance (i.e., EGFR C797S) to this third-generation EGFR inhibitor are evolving. Whether durable control of subsequently osimertini

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::298bf4808b59c341d940fcd8560cc798
https://doi.org/10.1016/j.jtho.2019.07.016

Zobrazit plný text záznamu

An up-to-date evaluation of abiraterone for the treatment of prostate cancer

Autor: Julia S Stevens, Jason Shpilsky, Glenn J. Bubley

Publikováno v: Expert opinion on pharmacotherapy. 22(10)

Introduction: Abiraterone acetate, an oral 17-alpha-hydroxylase inhibitor, effectively prevents the synthesis of androgens from steroid precursors. Abiraterone has become a standard of care in patients with metastatic prostate cancer due to its effic

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d2ef73c7cb8d56a52b6621c3f8c5a19
https://pubmed.ncbi.nlm.nih.gov/33856289

Zobrazit plný text záznamu

Five Questions for Residency Leadership in the Time of COVID-19: Reflections of Chief Medical Residents From an Internal Medicine Program

Autor: Jason Shpilsky, Jim Doolin, Bess M. Flashner, Kelly L. Graham, Shana Rakowsky, Shu Yang, Zachary Reese, C. Christopher Smith

Publikováno v: Academic Medicine

The COVID-19 pandemic has drastically affected the traditional methods residency programs use to train their residents. Chief residents serve a unique role as part of the residency leadership to foster the education and development of the residents.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::131a12108f10bac7e007ea52ef8a94f7

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání